Supplementary Figure S1 from Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial
Year: 2026
Type: supplementary-materials
Abstract: Forest plot for the GEICAM/9906 translational study cohort primary endpoint of DRFI, on the FEC vs FEC + P arms for SETER/PR cutpoint “0.75” categories.
Authors: Miguel Martín, Alvaro Rodriguez-Lescure, Cristina Reboredo, Eveline Chen, Manuel Ruiz-Borrego, Ana Santaballa Bertran, Cesar A. Rodríguez, Noelia Martinez-Jañez, Emilio Alba, Kevin Tran, Ignacio Pelaez Fernandez, Isabel Álvarez, Miguel A. Seguí, Alberto de la Cruz, Vicente Valero, Antonio Antón-Torres, Raquel Andrés, Kepa Amillano, José J. Ponce-Lorenzo, Severina Dominguez Fernandez, Jesus Herranz, Raul Rincon, Rosalía Caballero, Angel Guerrero-Zotano, Federico Rojo, W. Fraser Symmans
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W7204946145